J. Lettieri

发表

Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics

M. Radtke, C. Lathia, P. Sundaresan, 2006, Cancer Chemotherapy and Pharmacology.

Exposure–Response Modeling and Simulation of Progression‐Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer

B. Ploeger, G. Jentsch, M. Schlumberger, 2019, Clinical and translational science.

Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors

F. Marmé, J. Lettieri, C. Gomez-Roca, 2018, Cancer Chemotherapy and Pharmacology.

Assessment of the Effects of Renal Impairment on the Pharmacokinetics of the Soluble Guanylate Cyclase Activator Cinaciguat After a Single Intravenous Dose

A. Mazzu, P. Sundaresan, J. Lettieri, 2012, Journal of clinical pharmacology.

Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin

K. Lasseter, J. Lettieri, R. W. Frost, 1992, Antimicrobial Agents and Chemotherapy.

Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects

F. Hafner, M. Radtke, K. Diefenbach, 2017, Cancer Chemotherapy and Pharmacology.

Effect of Quinolone Antimicrobials on Theophylline Pharmacokinetics

J. Lettieri, E. Casabar, C. Adair, 1989, Journal of clinical pharmacology.

Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin.

J. Lettieri, R. Polk, J. Toscano, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effect of Food on the Pharmacokinetics of a Single Oral Dose of Moxifloxacin 400mg in Healthy Male Volunteers

Patrick M Liu, R. Vargas, J. Lettieri, 2001, Clinical Pharmacokinetics.

Optimizing wound healing in the face after laser abrasion.

G. Skover, R. Fitzpatrick, J. Lettieri, 2002, Journal of the American Academy of Dermatology.

Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat

J. Lettieri, A. Nadel, W. Mück, 2013, BMC Pharmacology and Toxicology.

Effects of cardiopulmonary bypass surgery on intravenous ciprofloxacin disposition

S. Levitsky, J. Lettieri, K. Rodvold, 1993, Antimicrobial Agents and Chemotherapy.

Safety and Tolerance of Intravenous Nimodipine

P. Sundaresan, N. Cutler, J. Lettieri, 1994, The Annals of pharmacotherapy.

Influence of renal function on the pharmacokinetics of cerivastatin in normocholesterolemic adults

Meilin Liu, A. Mazzu, P. Sundaresan, 2000, European Journal of Clinical Pharmacology.

Impact of ciprofloxacin on theophylline clearance and steady-state concentrations in serum

J. Lettieri, J. Schwartz, K. Bachmann, 1988, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects

J. Lettieri, J. Wilton, D. Nix, 1995, Antimicrobial agents and chemotherapy.

Pharmacokinetics of a Once-Daily Oral Dose of Moxifloxacin (Bay 12-8039), a New Enantiomerically Pure 8-Methoxy Quinolone

J. T. Sullivan, J. Lettieri, P. Leese, 1999, Antimicrobial Agents and Chemotherapy.

Application of single-donor fibrin glue to burns.

W. Spotnitz, J. Lettieri, J. Baker, 1988, The Journal of burn care & rehabilitation.

Pharmacokinetics, Safety, and Tolerability of Single‐Dose Intravenous Moxifloxacin in Pediatric Patients: Dose Optimization in a Phase 1 Study

H. Stass, J. Lettieri, S. Willmann, 2019, Journal of clinical pharmacology.

Improved pharmacological activity via pro-drug modification: comparative pharmacokinetics of sodium gamma-hydroxybutyrate and gamma-butyrolactone.

J. Lettieri, H. Fung, 1978, Research communications in chemical pathology and pharmacology.

Evaluation and development of gas chromatographic procedures for the determination of γ-hydroxybutyric acid and γ-butyrolactone in plasma

J. Lettieri, H. Fung, 1978 .

Pharmacokinetics of Moxifloxacin in Special Populations

H. Stass, J. Lettieri, 1999, Drugs.

Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin

Jerome J. Schentag, W. Watson, J. Lettieri, 1989, Clinical pharmacology and therapeutics.

Ciprofloxacin Pharmacokinetics After a Standard or High‐Fat/High‐Calcium Breakfast

A. Dietz, J. Lettieri, A. Heyd, 1989, Journal of clinical pharmacology.

Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin

A. Mazzu, K. Lasseter, J. Lettieri, 2000, Clinical pharmacology and therapeutics.

Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses

M. Rogge, R. Echols, J. Lettieri, 1992, Antimicrobial Agents and Chemotherapy.

Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding

J. Lettieri, R. Quintiliani, C. Nightingale, 1989, Antimicrobial Agents and Chemotherapy.

Absorption and first-pass metabolism of 14C-gamma-hydroxybutyric acid.

J. Lettieri, H. Fung, 1976, Research communications in chemical pathology and pharmacology.

Dose-dependent pharmacokinetics and hypnotic effects of sodium gamma-hydroxybutyrate in the rat.

J. Lettieri, H. Fung, 1979, The Journal of pharmacology and experimental therapeutics.

Ciprofloxacin pharmacokinetics in burn patients

J. Lettieri, J. Garrelts, S. Kowalsky, 1996, Antimicrobial agents and chemotherapy.

Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation.

M. V. Miles, R. Echols, J. Lettieri, 1997, The Pediatric infectious disease journal.

Comparative pharmacokinetics and safety of ciprofloxacin 400 mg i.v. thrice daily versus 750 mg po twice daily.

R. Echols, J. Lettieri, A. Shah, 1994, The Journal of antimicrobial chemotherapy.

Determination of the Concentration of Ciprofloxacin in Prostate Tissue Following Administration of a Single, 1000 mg, Extended-Release Dose

H. Stass, J. Lettieri, J. Lugg, 2008, Journal of chemotherapy.

LC separation and induced fluorometric detection of rivastatin in blood plasma.

J. Lettieri, G. Krol, G. Beck, 1993, Journal of pharmaceutical and biomedical analysis.

Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers.

A. Mazzu, J. Lettieri, P. Weber, 1999, Clinical therapeutics.

Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor.

A. Mazzu, K. Ochmann, J. Lettieri, 1997, The Journal of international medical research.

Pharmacokinetics and Metabolism of Radiolabeled Nimodipine

A. Jain, F. Mcmahon, J. Lettieri, 1988 .

CO2 Laser Resurfacing: Recognizing and Minimizing Complications

J. Lettieri, T. L. Roberts, L. B. Ellis, 1996 .

Effects of competitive red blood cell binding and reduced hematocrit on the blood and plasma levels of [14C]Indapamide in the rat.

J. Lettieri, S. Portelli, 1983, Journal of Pharmacology and Experimental Therapeutics.

Lidocaine Diffusion in Five Tissue Expanders: An In Vitro and In Vivo Study

D. Herold, J. Lettieri, D. Berman, 1991, Annals of plastic surgery.

Steroid and Benzyl Alcohol Diffusion Through Tissue Expanders and Double Lumen Breast Implants

D. Herold, Yuh-Feng Lin, J. Lettieri, 1991, Annals of plastic surgery.

Lidocaine permeability in silicone tissue expanders: an in vitro analysis.

R. F. Morgan, R. Edlich, D. Herold, 1989, Plastic and reconstructive surgery.

Effect of hepatic impairment on sorafenib pharmacokinetics: Results of a multicenter, open-label, single-dose, phase I trial.

C. Lathia, A. Mazzu, J. Lettieri, 2011, Journal of Clinical Oncology.

Effects of beano on the tolerability and pharmacodynamics of acarbose.

J. Lettieri, B. Dain, 1998, Clinical therapeutics.

Disposition and Pharmacokinetics of 14C‐Nitrendipine in Healthy Volunteers

J. Lettieri, G. Krol, D. Burkholder, 1987 .

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study

C. Köhne, G. Folprecht, D. Strumberg, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers.

S. Gettinger, N. Rizvi, M. Hellmann, 2015, Clinical Lung Cancer.

Evaluation and development of gas chromatographic procedures for the determination of gamma-hydroxybutyric acid and gamma-butyrolactone in plasma.

J. Lettieri, H. Fung, 1978, Biochemical medicine.

Pharmacokinetics, Pharmacodynamics, and Safety of Metrifonate in Patients with Alzheimer's Disease

B. Gulanski, F. Schmitt, W. Markesbery, 1998, Journal of clinical pharmacology.

109 Lack of pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin

A. Mazzu, J. Lettieri, A. Heller, 1997 .

Pharmacokinetics of Nitrendipine in Elderly and Young Healthy Volunteers

A. Jain, F. Mcmahon, J. Lettieri, 1987 .

The effect of cirrhosis on the steady‐state pharmacokinetics of oral ciprofloxacin

K. Lasseter, J. Lettieri, G. Krol, 1989, Clinical pharmacology and therapeutics.

Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat

J. Lettieri, A. Nadel, W. Mück, 2013, BMC Pharmacology and Toxicology.

Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects.

J. Lettieri, A. Shah, D. Sica, 1996, The Journal of antimicrobial chemotherapy.

Multiple Dose Pharmacokinetics of Four Different Doses of Nisoldipine in Hypertensive Patients

M. Harrison, A. Mazzu, M. Chandler, 1992, Journal of clinical pharmacology.

Bioequivalence of Different Nitrendipine Tablet Dosage Formulations

A. Mazzu, J. Lettieri, R. Taylor, 1987 .

111 Pharmacokinetics of cerivastatin administration with and without food in the morning and evening

A. Mazzu, J. Lettieri, A. Heller, 1997 .

The Influence of Age and Gender on the Pharmacokinetics of Moxifloxacin

Patrick Y. Liu, J. T. Sullivan, J. Lettieri, 2001, Clinical Pharmacokinetics.

Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial.

R. Paschke, L. Bastholt, M. Schlumberger, 2014 .

A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer

David C. Smith, Robin L. Jones, J. Bendell, 2015, Cancer Chemotherapy and Pharmacology.

Craniofacial Suture Stenosis: Morphologic Effects

J. Lettieri, A. Cronin, John A. Persing, 1991, Plastic and reconstructive surgery.

No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects

J. Lettieri, F. Huang, C. Peña, 2017, Thyroid : official journal of the American Thyroid Association.

Percutaneous butyrolactone absorption in rats.

J. Lettieri, H. Fung, Robert A. Bochner, 1979, Journal of pharmaceutical sciences.

Absolute bioavailability of moxifloxacin.

H. Stass, J. T. Sullivan, J. Lettieri, 1999, Clinical therapeutics.

Effects of renal impairment on the pharmacokinetics of sorafenib and its metabolites

A. Mazzu, M. Kipnes, T. Marbury, 2007 .

Influence of Age on the Safety, Tolerability, and Pharmacokinetics of the Novel HMG‐CoA Reductase Inhibitor Cerivastatin in Healthy Male Volunteers

A. Mazzu, J. Lettieri, A. Heller, 1998, Journal of clinical pharmacology.

PHARMACOKINETICS OF NISOLDIPINE COAT‐CORE FORMULATION IN SUBJECTS WITH LIVER CIRRHOSIS

P. Sundaresan, K. Lasseter, J. Lettieri, 1995, American journal of therapeutics.